Featuring perspectives from Dr Petros Grivas, including the following topics:

• Collaboration between urologists and medical oncologists for the management of urothelial bladder cancer (UBC) (0:00)
• Evolution of treatment modalities for non-muscle-invasive bladder cancer (NMIBC) (11:16)
• Perspective on recurrence mechanisms of NMIBC (22:21)
• Potential implications of circulating tumor DNA-based research in the management of bladder cancer (25:27)
• Importance of collaborative care for patients with bladder cancer (42:02)
• Frequency of HER2 expression and approach to HER2 testing for metastatic UBC (mUBC); activity of trastuzumab deruxtecan (T-DXd) in HER2-positive solid tumors (46:57)
• Monitoring and management of T-DXd-associated side effects (1:00:47)
• Efficacy and ongoing investigation of the HER2-targeted antibody-drug conjugate disitamab vedotin; other promising agents and strategies under investigation for mUBC (1:07:32)
• Results from the Phase III PROOF 302 trial of infigratinib versus placebo for patients with high-risk resected UBC with an FGFR3 genomic alteration (1:11:22)
• Potential association between intravesical bacillus Calmette-Guérin administration and lower risk of being diagnosed with Alzheimer’s disease in patients with bladder cancer; feasibility of internet-based, patient-driven germline genetic testing (1:16:12)

CME information and select publications

Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, including the following topics:

• Introduction (0:00)
• First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44)
• The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08)
• Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25:17)
• The Selection and Sequencing of Therapies for Relapsed/Refractory CLL (35:45)
• The Tolerability of Available Bruton Tyrosine Kinase (BTK) Inhibitors (40:43)
• The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax (48:48)
• Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (1:04:19)
• Cytokine Release Syndrome and Neurotoxicity with Bispecific Antibodies (1:06:25)
• Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy (1:10:44)
• Bispecific Antibodies for the Management of Follicular Lymphoma (1:18:19)
• The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (1:24:17)
• Other Practical Considerations with the Use of Bispecific Antibodies (1:40:59)

NCPD information and select publications

Featuring perspectives from Dr William J Gradishar, Dr Virginia Kaklamani, Dr Erica Mayer and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• Addition of Ovarian Function Suppression (OFS) to Adjuvant Endocrine Therapy for Premenopausal Patients with Hormone Receptor (HR)-Positive Breast Cancer — Dr Gradishar (4:49)
• Case: A woman in her mid 20s with HR-positive, HER2-positive intraductal carcinoma (IDC) who received ovarian suppression with TAC chemotherapy and concurrent trastuzumab/pertuzumab followed by tamoxifen (30:48)
• Case: A woman in her late 30s with HR-positive, HER2-negative IDC and no nodal involvement who received postoperative chemoradiation therapy followed by tamoxifen and is considering ovarian suppression (39:31)
• Role of OFS in Preserving Fertility and/or Ovarian Function in Premenopausal Patients – Dr Mayer (44:55)
• Case: A woman in her early 30s with HR-positive, HER2-positive (IHC 3+) IDC recommended to receive perioperative TCHP who is interested in fertility preservation (1:11:15)
• Case: A woman in her mid 30s presenting with ER-positive, HER2-negative breast cancer during early pregnancy who received preoperative TAC and had pathologic complete response at surgery (1:14:18)
• Tolerability and Toxicity of OFS – Dr Kaklamani (1:21:21)
• Case: A woman in her mid 30s, uninterested in fertility preservation, who received chemotherapy and TAC followed by tamoxifen and abemaciclib for ER-positive, HER2-negative breast cancer (1:39:42)
• Case: A premenopausal woman in her late 40s with a 3.6-cm breast tumor and a Recurrence Score (RS) of 26 who becomes amenorrheic with chemotherapy and TC (1:43:32)
• Other Practical Considerations in the Application of OFS – Dr Wander (1:46:29)
• Case: A woman in her early 50s with HR-positive, HER2 IHC 2+ invasive lobular carcinoma and a RS of 15 who declined chemotherapy and opted to stop adjuvant leuprolide after 1 year (1:59:56)
• Case: A woman in her early 40s with HR-positive, HER2 IHC 1+ breast cancer who has no interest in fertility preservation and significant residual disease at surgery (2:14:06)

CME information and select publications